Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.48 |
| ▸ | NPY4R | P50391 | 10/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY1R | P25929 | 7/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.42 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045521 | 1.00 | MC4R (0.48) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22330634 | 0.94 | QRFPR (0.48) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL20045525 | 0.94 | QRFPR (0.48) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30294160 | 0.89 | FOLH1 (0.45) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22485383 | 0.89 | NPY4R (0.51) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22339066 | 0.89 | NPY4R (0.51) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23968026 | 0.87 | MC4R (0.56) | MC4RKISS1R | |
| SCHEMBL20046066 | 0.87 | MC4R (0.56) | MC4RKISS1R | |
| SCHEMBL20045522 | 0.87 | MC4R (0.56) | MC4RKISS1R | |
| SCHEMBL30294162 | 0.87 | MC4R (0.56) | MC4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591367-B2 | Melanocortin-1-receptor agonists | DSM IP ASSETS B.V. (NL) | 2023-02-28 | — | — | US | disclosed |
| EP-3523316-B1 | MELANOCORTIN-1-RECEPTOR AGONISTS | DSM IP ASSETS BV (NL) | 2021-11-03 | — | — | EP | disclosed |
| US-20210277058-A1 | MELANOCORTIN-1-RECEPTOR AGONISTS | DSM IP ASSETS B.V. (NL) | 2021-09-09 | — | — | US | disclosed |
| WO-2020161255-A1 | NOVEL METHOD FOR REDUCING HAIR GROWTH | DSM IP ASSETS B.V. (NL) | 2020-08-13 | — | — | WO | disclosed |
| EP-3692978-A1 | NOVEL METHOD | DSM IP Assets B.V. (NL) | 2020-08-12 | — | — | EP | disclosed |
| WO-2018065345-A1 | MELANOCORTIN-1-RECEPTOR AGONISTS | DSM IP ASSETS B.V. (NL) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277058-A1 | MELANOCORTIN-1-RECEPTOR AGONISTS | MC1R, MC3R, MC5R | MC4R 4/4885NPY4R 51/4885NPY5R 39/4885 |
| US-11591367-B2 | Melanocortin-1-receptor agonists | MC1R, MC3R, MC5R | MC4R 4/4885NPY4R 51/4885NPY5R 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.